The Unicorn Foundation is pleased to financially assist the Peter MacCallum Cancer Centre in making the recently published research – Assessment of Predictors of response and long-term survival of patients with Peptide Receptor Chemoradionuclide Therapy (PRCRT) 'open access' and available to all.
This significant paper adds to the burgeoning evidence of the clinical utility of PRCRT in the treatment of neuroendocrine tumours (NET).
Outside the European Centres, Australian Nuclear Medicine Physicians (Turner, Hicks, Hofman and others) are gaining the recognition and respect that is well deserved, and as a result of their 'collective' efforts, placing Australia at the forefront of neuroendocrine cancer management.
The Unicorn Foundation, our Australian and New Zealand NET patients are grateful and fortunate to have experienced and passionate Doctors who have patient focussed care as their raison d'être.
Please download this paper and distribute it widely amongst your networks. We need the medical community and broader community to become aware of the benefits of PRCRT.
Dr John Leyden